Buy, Sell or Hold: Docusign (DOCU-Q) — Stock Predictions at Stockchase

Home

Daily Stock Opinions and Ratings

Docusign (DOCU-Q)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

NASDAQ:DOCU

78.01

3.81 (5.13%) 1d

2 Big Technology Stocks That Are Back Stocks sink, oil rises U.S markets close down for the week, TSX steadier

Investor Insights

This summary was created by AI, based on 3 opinions in the last 12 months.

DocuSign (DOCU-Q) is a company that has shown promising potential for future earnings, with a free cash flow yield of 5.5%. Experts highlight its recent performance, noting a beat in Q2 earnings and a recovery trajectory post-pandemic, making it an attractive investment at a fair valuation with a price-to-earnings (PE) ratio of 16x and an appealing 8% free cash flow yield. While the company has experienced significant growth, some experts believe it has reached its growth limits, yet it still maintains a dominant position in its market and is viewed as a potential acquisition target. The management team's conservative forecasting is also seen as a positive factor, contributing to investor confidence that the company will exceed earnings expectations in the future.

Consensus

Positive

Valuation

Fair Value

Similar

Adobe Systems, ADBE-Q

BUY

Decent earnings lie ahead. Has a 5.5% free cash flow yield.

STRONG BUY

Their Q2 earnings beat. A pandemic darling that then crashed. But now it trades at a fair valuation and strong free cash flow. She bought it last September is up 35%. Trades at 16x PE and has a 8% free cash flow yield. Great managers who underpromise, so they will beat their quarter. Has real secular growth.

HOLD

It has maxed out to a large degree on the growth side. It is still dominant in the space and could be an acquisition target.

DON'T BUY

Dominates this business, but ADBE has entered the space. Stock's gone sideways. Software is not unique, and competition will show up. Perhaps a bigger player like MSFT would buy it and incorporate the technology.

BUY

Has a new CEO since last year and he's aggressively cut costs. Last month, they reported one of their best quarters in years, but shares didn't get any traction.

DON'T BUY

Likes and uses its software, but it's still too close to its post-Covid hangover to buy. There are too many competitors, too.

BUY ON WEAKNESS

Allan Tong’s Discover Picks Taking a step back, DOCU revenues have climbed from $250 million in 2016 to $2.1 billion in its last fiscal year. Meanwhile, cash levels are rising. Flashforward to last week's report in which EPS clocked in at $0.44. That was actually down 6% from a year ago, but higher than the expected $0.42. Also impressing the street were revenues of $622.2 million beating $602 million (a 22% increase YOY). The company issued a rosy forecast of $626 million in revenues vs. the street's $625 million. Read 2 Big Technology Stocks That Are Back for our full analysis.

BUY ON WEAKNESS

Are spectacular buys in the tech space, even pandemic tech winners like Docusign. It just reported a surprise beat and shares are soaring. Post-Covid, it sold off hard and fast, but they still had a business going. Buy during sell-offs.

BUY ON WEAKNESS

Downgraded a lot today BOA downgraded it to a sell today, but he added to his holdings today. It's down 80% from its pandemic highs, but its products are everywhere. Not a great investment, sure, but DOCU is an essential part of any business that already uses it, and businesses rarely change their service systems. Also, companies and countries are reacting to the Russian invasion of Ukraine--they're asking, in which country is my data residing? He's in pain, but is averaging down. DOCU is a long-term bet. He's known the management since they were private--he's confident DOCU can pivot. He projects double-digit returns in 18 months.

DON'T BUY

Wall Street has left certain "pandemic" stocks for dead. They offer a valuable product that will expand its reach. But more business deals will be done face to face after Covid. DOCU is trading at 56x PE even after falling from highs. DOCU flew too high during Covid.

DON'T BUY

Reported a miss He had puts at the 95 put strike. My gosh. When this stock is taken out, it's not at 5-10%, but a quarter of the value of the company. Not good.

DON'T BUY

Represents change from risk-on to risk-off in markets. Peaked at over $300, now below $100. No fundamental floor, so nothing to support it besides a concept, albeit a good one. Extremely expensive at 7x revenue, doesn't make any money. Don't be lured by stocks that fall precipitously, as there may be no end in sight.

DON'T BUY

Cathy Wood bought a ton of shares after share plunged DOCU has a bright future, but this in the penalty box for a few quarters. As for Wood, he respects her, but wishes she would be more selective in what she buys.

DON'T BUY

They reported a terrible quarter and sank 42%. A poorly executed quarter and a slowdown in business that the CEO didn't see. But investors hid behind this in the wake of Omicron and got hit badly today. DOCU dragged down other tech stocks, too. It was trading at 150x earnings which made investors consider the value of tech stocks in general.

DON'T BUY

A Covid play, trading at 150x earnings, which is too rich. Pass though he's a little on the fence about this because he's a huge believer in their product.

Showing 1 to 15 of 28 entries

Docusign(DOCU-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 3

Stockchase rating for Docusign is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Docusign(DOCU-Q) Frequently Asked Questions

What is Docusign stock symbol?

Docusign is a American stock, trading under the symbol DOCU-Q on the NASDAQ (DOCU). It is usually referred to as NASDAQ:DOCU or DOCU-Q

Is Docusign a buy or a sell?

In the last year, 3 stock analysts published opinions about DOCU-Q. 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Docusign.

Is Docusign a good investment or a top pick?

Docusign was recommended as a Top Pick by on . Read the latest stock experts ratings for Docusign.

Why is Docusign stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Docusign worth watching?

3 stock analysts on Stockchase covered Docusign In the last year. It is a trending stock that is worth watching.

What is Docusign stock price?

On 2025-04-23, Docusign (DOCU-Q) stock closed at a price of $78.01.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Docusign (DOCU-Q)

NASDAQ:DOCU

Docusign(DOCU-Q)

Docusign(DOCU-Q)

Docusign(DOCU-Q)

Docusign(DOCU-Q)

Docusign(DOCU-Q)

Docusign(DOCU-Q)

Docusign(DOCU-Q)

Docusign(DOCU-Q)

Docusign(DOCU-Q)

Docusign(DOCU-Q)

Docusign(DOCU-Q)

Docusign(DOCU-Q)

Docusign(DOCU-Q)

Docusign(DOCU-Q)

Docusign(DOCU-Q)

Docusign(DOCU-Q) Rating

Docusign(DOCU-Q) Frequently Asked Questions

What is Docusign stock symbol?

Is Docusign a buy or a sell?

Is Docusign a good investment or a top pick?

Why is Docusign stock dropping?

Is Docusign worth watching?

What is Docusign stock price?

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Kim Bolton

Jim Cramer - Mad Money

Paul Harris, CFA

The Panic-Proof Portfolio (Stockchase Research)

Larry Berman CFA, CMT, CTA